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Abstract
Objectives Almost 20% of people smoke tobacco worldwide—a
percentage projected to rise in many poor countries. Smoking has been
linked to increased individual risk of tuberculosis infection and mortality,
but it remains unclear how these risks affect population-wide tuberculosis
rates.
Design We constructed a state transition, compartmental, mathematical
model of tuberculosis epidemics to estimate the impact of alternative
future smoking trends on tuberculosis control. We projected tuberculosis
incidence, prevalence, and mortality in each World Health Organization
region from 2010 to 2050, and incorporated changing trends in smoking,
case detection, treatment success, and HIV prevalence.
Results The model predicted that smoking would produce an excess
of 18 million tuberculosis cases (standard error 16-20) and 40 million
deaths from tuberculosis (39-41) between 2010 and 2050, if smoking
trends continued along current trajectories. The effect of smoking was
anticipated to increase the number of tuberculosis cases by 7% (274
million v 256 million) and deaths by 66% (101 million v 61 million),
compared with model predictions that did not account for smoking.
Smoking was also expected to delay the millennium development goal
target to reduce tuberculosis mortality by half from 1990 to 2015. The
model estimated that aggressive tobacco control (achieving a 1%
decrease in smoking prevalence per year down to eradication) would
avert 27 million smoking attributable deaths from tuberculosis by 2050.
However, if the prevalence of smoking increased to 50% of adults (as
observed in countries with high tobacco use), the model estimated that
34 million additional deaths from tuberculosis would occur by 2050.
Conclusions Tobacco smoking could substantially increase tuberculosis
cases and deaths worldwide in coming years, undermining progress
towards tuberculosis mortality targets. Aggressive tobacco control could
avert millions of deaths from tuberculosis.
Introduction
Global health experts set a millennium development goal to
reduce tuberculosis prevalence and mortality by half between
1990 and 2015.
1 2 To achieve this target, programmes of
tuberculosis control have focused on detecting and treating
activetuberculosiscasestoreducetheirinfectiousness,breaking
the transmission chain.
3 Several countries with a high burden
of tuberculosis, however, are unlikely to meet the millennium
development goal targets despite high levels of detection and
treatment, leading the World Health Organization to question
whetherkeyriskfactorsforinfectionmustalsobeaddressed.
3 4 5
Tobacco smoking is a prevalent risk factor for tuberculosis.
Nearly a fifth of the world’s population smokes tobacco or uses
othertobaccoproducts.
6Mostcigarettesaresmokedincountries
with a high prevalence of tuberculosis, where multinational
tobacco companies have expanded their markets.
7 8 Recent
reviews show weak infrastructure to regulate tobacco use and
increasing smoking in the areas with endemic tuberculosis.
6 9
Smoking increases the risk of latent tuberculosis by a factor of
1.9 (95% confidence intervals 1.6 to 2.3), active tuberculosis
by 2.0 (1.5 to 2.6), and death from tuberculosis by 2.6 (1.8 to
3.6),afteradjustingforsocioeconomicstatus(table1⇓).
10These
moderate increases in individual risk of tuberculosis due to
smoking might translate into a large impact at the population
level, owing to the high prevalence of smoking. In India, for
example, 38% of deaths from tuberculosis among middle aged
men are attributed to smoking,
18 costing India’s economy three
times its tuberculosis budget.
19
Recent studies have used the population attributable risk of
infection
20 to calculate the potential impact of smoking on
tuberculosis, linearly extrapolating the magnitude of increased
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RESEARCHtuberculosis cases and deaths as a result of individual increases
inrelativerisk.
10 18Becausetuberculosisisaninfectiousdisease,
however, an increase in cases can result in the further increase
ofadditionalnewcasesatanexponentialratherthanlinearrate,
but only up to levels of saturation based on the degree of risky
contact among infected and uninfected individuals in a
population.
21Furthermore,tuberculosisisalongcoursedisease,
and many individuals relapse or are not cured completely, with
varying levels of protection from new active disease based on
immunityfrompreviousinfectionaswellaschemoprophylaxis
given to people with latent infections.
22 Finally, when a risk
factor not only increases the risk of primary infection but also
increases the risk of mortality, it remains unclear how future
prevalence will change, because the rise in mortality could
outweigh the increase in incidence (Little’s law:
prevalence=incidence×duration of disease, where duration of
diseaseisreducedbyhighermortality),producingnon-intuitive
changes to the dynamics of epidemics as well as the timing and
effects of ongoing control measures.
21
Mathematically modelling a population allows us to view how
disease pathogenesis and the process of infection, progression,
and mortality can change while the parameters that affect
multiple points of disease infection and control are modified.
Sofar,mathematicalmodelsoftuberculosishaveaccountedfor
HIV, new tuberculosis detection technologies, and drug
resistance,
23 24 but not smoking. Our analysis aimed to provide
an estimate of the impact of smoking and different scenarios
for control of smoking on future trajectories of tuberculosis.
We developed a state transition, compartmental, mathematical
model of tuberculosis epidemics to estimate the effect of
smoking on tuberculosis.
Methods
Structure of mathematical model
The model (fig 1⇓) consisted of differential equations that
described tuberculosis infection, pathogenesis, and mortality
among populations older than 15 years (web appendix). It
incorporated transition states representing susceptibility to
tuberculosis infection, latent tuberculosis infection, and active
tuberculosis disease. We derived natural history parameters
describing the pathogenesis of tuberculosis in the model from
studies of populations before widespread tobacco use, to avoid
confounding our modifications that accounted for smoking
(table 1).
The model incorporated smoking by estimating the population
in each WHO region that actively smokes tobacco each year,
to calculate the number of tuberculosis infections and deaths
among smokers as well as the number of secondary infections
anddeathsresultingfromeachnewcaseofsmokingattributable
tuberculosis. The model also included increased rates of
non-tuberculosis mortality among smokers (for example, from
cardiovascular disease). Therefore, we could see the effect of
tobacco control on deaths from tuberculosis alone, since
smokingrelateddeathsnotrelatedtotuberculosisweretabulated
separately.
We selected the model by comparing it with two previously
published models
25 26 and using Akaike’s information criterion
todeterminewhichmodelbestfitavailabledatausingthefewest
number of parameters (maximising accuracy while minimising
uncertainty).
27Themodelinfig1producedasignificantlybetter
selectionscorethanthetwoalternatives(differenceinAkaike’s
informationcriterionscores>10)
28whenfittoannualtuberculosis
incidence, prevalence, and mortality rates in 1990-2009 from
each WHO region (web appendix).
29 We organised our
simulationsbyWHOregionforcomparisonwithpreviousWHO
analyses,
12 although the model equations could apply to any
population (web appendix).
Modelling approach and underlying
assumptions
The model projects future tuberculosis cases and deaths from
2010to2050,incorporatingbirthandnon-tuberculosismortality
rates specific to each WHO region.
13 It also included rates of
tuberculosis case detection and treatment success to simulate
standardinternationalprotocols,
29sincethesefactorsreducethe
duration of infectiousness and risk of mortality in tuberculosis.
Toprojectfutureexpectedratesofcasedetectionandtreatment
success rates, we fit saturating exponential functions to annual
tuberculosis case detection and treatment success data from
1994 to 2008 for each region,
29 projecting future rates toward
asymptotes of 80% case detection and 90% treatment success
based on previous WHO analyses.
30
We also used the model to estimate HIV prevalence trends and
calculate how tuberculosis disease and mortality rates would
increaseamongHIVinfectedpeople.WesimulatedannualHIV
prevalence by fitting double logistic curves to adult HIV
prevalence data from 1990 to 2010.
31
Themodelestimatedsmokingprevalencefromdataontobacco
demand
32 (tonnes of tobacco sold per capita annually since
1970) by calculating the ratio between smoking prevalence and
demand in 1991, the only year when both regional smoking
prevalence and tobacco demand data were available.
33 We then
multiplied each region’s annual tobacco demand by this
prevalence-to-demand ratio to estimate the annual smoking
prevalence, which we corrected for population age and sex
distributions.
13 To establish face validity of these smoking
prevalence estimates, we verified that the projections were
within 5% of WHO’s point prevalence smoking surveys
available intermittently between 1990 and 2009.
33 We assigned
former smokers the same tuberculosis risks as never smokers,
consistentwithrecentanalysesoftuberculosisnaturalhistory.
34
We constructed three scenarios for possible future smoking
trends. The baseline scenario assumed that smoking rates in
each region would continue changing at the same annual rate
as from 2005 to 2010 up to a maximum of 40% (the maximum
in any overall WHO region so far
35). The pessimistic scenario
assumed that smoking prevalence rates would rise by 0.72%
per year, twice the global average rate in 2005-10, reaching a
maximum of 50% prevalence (the highest rate observed in any
individual country among people older than 15 years
35). The
optimistic scenario assumed that smoking prevalence would
follow the baseline simulation until 2015, and then fall by 1%
per year (the rate of decline observed among US states with
aggressive tobacco control programmes
36 and a new goal in
some nations
37) until reaching 0%.
Sensitivity and uncertainty analyses
Weusedtwoapproachesforthesensitivityanalysis.Firstly,we
added the effect of passive smoking to the baseline model.
Passive smoking is thought to increase the relative risk of
tuberculosisinfection(butnotmortality)byamagnitudesimilar
to that among active smokers.
10 38 We assumed that passive
smoking increased the effective smoke exposed population by
40% (95% confidence intervals 10% to 60%), based on an
aggregate estimate among low income and middle income
countries.
35
Secondly, HIV and smoking might have a synergistic impact,
such that HIV positive smokers die more rapidly than if they
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simulated a scenario in which people affected by both HIV and
smoking would lose an extra seven months of life because of
the possible synergy (beyond the mortality effects of HIV and
smoking individually), based on limited cohort data available
so far.
39 40
We used Monte Carlo simulations to estimate the uncertainty
in all of our simulations by sampling from the probability
distributionsoftheinputparameters.Wereportedthemeanand
standard error from 10 000 simulations.
Results
Baseline scenario
The model estimated that smoking would cause 18 million
excess cases of tuberculosis (standard error 16-20) between
2010 and 2050. The model projected a total of 256 million
tuberculosis cases if it did not account for smoking (when the
model was run with 0% smoking prevalence for all years), and
274 million cases if it included smoking. The model also
estimated that smoking would cause 40 million excess deaths
from tuberculosis (39 to 41) from 2010 to 2050 (61 million
without smoking impact v 101 million deaths with smoking
impact). Increases in tuberculosis incidence ranged from 5%
(in the western Pacific region) to 42% (in the eastern
Mediterranean) (fig 2⇓), and tuberculosis mortality increases
ranged from 64% (in Europe) to 135% (in the eastern
Mediterranean), when comparing the model ignoring smoking
with the simulation incorporating current smoking trends (fig
3⇓). The model estimated that the Americas, eastern
Mediterranean, South |East Asian, and western Pacific regions
wouldmissthemortalitymillenniumdevelopmentgoalbecause
of smoking.
Smoking reduces the point prevalence of active tuberculosis by
increasing tuberculosis mortality rates (fig 4⇓). This reduced
tuberculosis prevalence does not reflect improved control, but
rather a higher number of deaths than new cases. Despite the
slightlylowernumberofactivetuberculosiscasesthatcaninfect
susceptiblepeople(thatis,aloweredprevalence),theheightened
individual risk of tuberculosis infection due to smoking still
produces a net increase in tuberculosis incidence (fig 2).
Themodelprojectedthatsmokingwoulddelaytheachievement
of the millennium development goal mortality target by at least
20 years in all WHO regions; smoking would also render the
target unreachable in the western Pacific (table 2⇓). Current
WHO projections for achieving the millennium development
goals were estimated by methods that ignored smoking; when
we excluded the effects of smoking in our model, it estimated
achievement dates within five years of WHO projections (table
2).
30 41
Pessimistic scenario
If smoking prevalence increased at twice the current rate to a
maximum of 50% prevalence, 290 million cumulative cases of
tuberculosis and 114 million cumulative deaths from
tuberculosis would be expected between 2010 and 2050—that
is, an increase of 6% and 12%, respectively, above the baseline
scenario. The model also projected an increase in the number
of smoking attributable tuberculosis cases (from 18 million
(standard error 16 to 20) to 34 million (29 to 39)) and smoking
attributable deaths from tuberculosis (from 40 million (39 to
41) to 114 million (113 to 115)) (web appendix). The model
estimatedthatachievementofthemillenniumdevelopmentgoal
mortality target would be delayed by at least 35 years in the
pessimistic scenario.
Optimistic scenario
If tobacco control efforts reduced smoking prevalence by 1%
per year in each WHO region from 2015 and eventually
eliminated smoking, 239 million cumulative tuberculosis cases
and 74 million cumulative deaths from tuberculosis would be
expected between 2010 and 2050—that is, a reduction of 13%
and 27%, respectively, from the baseline scenario. The model
projected aggressive tobacco control to avert 18 million
tuberculosis cases (standard error 14 to 22) and reduce the
number of smoking attributable deaths from tuberculosis from
40 million (39 to 41) to 13 million (12 to 14). The model also
projectedthataggressivetobaccocontrolwouldshortenthetime
to achieve the mortality millennium development goal (>15
years, optimistic scenario v >20 years, baseline scenario).
Passive smoking and HIV-smoking synergy
The model projected that passive smoking would increase the
cumulative number of tuberculosis cases and deaths between
2010 and 2050 by 35% and 167%, respectively, higher than the
baseline scenario, to 369 million tuberculosis cases and 149
million deaths from tuberculosis, respectively (incorporating
both active and passive smoking). Therefore, a total of 113
million tuberculosis cases (standard error 92 to 134) and 88
milliondeathsfromtuberculosis(86to90)wouldbeattributable
to smoking between 2010 and 2050. The model estimated that
passive and active smoking would delay achievement of the
millennium development goal mortality target by more than 26
years (compared with a delay of more than 20 years in the
baseline scenario incorporating only active smoking).
WeexpectedthepotentialsynergyofHIVandsmokingtohave
limited effect on mortality. In this model, an increase in
non-tuberculosis mortality among HIV infected smokers led to
death from other diseases before people developed active
tuberculosis. Although the total number of tuberculosis cases
fell to 271 million (with 14 million smoking attributable cases
(standard error 12 to 16), 1% lower than the baseline scenario),
the total number of deaths from tuberculosis remained at 101
million (40 million smoking attributable deaths (39 to 41),
similar to the baseline scenario).
Discussion
Principal findings
Smoking has not, traditionally, been incorporated into
mathematical models of tuberculosis, because risk factors with
a very high impact at the individual level on tuberculosis
prognosis have typically been the focus of such models.
42
Althoughtherelativeriskoftuberculosisfromsmokingislower
at an individual level than from risk factors such as HIV,
43 our
modelshowsthatthegreaternumberofsmokersworldwidecan
produce a large population attributable risk for tuberculosis.
Tobaccosmokingcouldsubstantiallyincreasetuberculosiscases
and deaths worldwide by 2050, and potentially delay major
goals to control tuberculosis mortality by at least 20 years if
current smoking trends continue. Aggressive tobacco control
measures could avert millions of deaths from tuberculosis over
the next four decades if these predictions are correct.
According to our model, the African, eastern Mediterranean,
and South East Asian WHO regions would be expected to have
the greatest increase in new tuberculosis cases attributable to
smoking (African rates would rise owing to the high risk of
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estimates also included new tuberculosis infections among
smokers and secondary infections among non-smokers, which
predicted tuberculosis cases would increase by 7% and deaths
by 66%, compared with model predictions that do not account
for the effect of smoking. If smoking trends were to increase
worldwideinaccordancewithongoingtobaccoindustryefforts,
9
the model predicted cases and deaths from tuberculosis to
increase beyond levels based on existing smoking trends, with
the highest burdens in Africa, the eastern Mediterranean, South
East Asia, and the western Pacific.
Aggressivelyloweringtheprevalenceoftobaccosmokingcould
reduce smoking attributable deaths from tuberculosis by 27
million by 2050, under the optimistic setting of a 1% reduction
insmokingrateperyear(seeninsomeUSstateswithsuccessful
tobacco control) to the point of eradication. The greatest
tuberculosisrelatedbenefitsfromtobaccocontrolwereexpected
in Europe, the western Pacific, and South East Asia. Our model
also accounted for smoking attributable deaths not related to
tuberculosis (for example, lung cancer), hence the effect of
tobaccoonmortalitywastheaddedtuberculosisimpactbeyond
that expected from other smoking related deaths.
Strengths and weaknesses of study
As with all mathematical models, our results are limited by the
modelling assumptions made. We modelled the effects of
smoking on tuberculosis infection and mortality in accordance
with published data, principally a meta-analysis of 33 studies
(web appendix). If effect sizes are small, the effect of
confounding third variables could be substantial; to keep this
effect to a minimum, we used relative risks derived from a
stratified analysis correcting for the impact of alcohol and
socioeconomic status. Smoking also produces pulmonary
lesions,whichthemselvescouldconfoundtuberculosisdiagnosis
by chest radiograph, leading to overdiagnosis among smokers.
Therefore, we based our risk estimates on studies with
independentconfirmationoftuberculosis(forexample,autopsy).
Nevertheless, studies of the impact of smoking on tuberculosis
tend to oversample clinic patients to derive control groups,
potentially underestimating the relative impact of tobacco and
generating low estimates of tobacco impact from our model.
Anothersourceofuncertaintyconcernsourprojectionsoffuture
trends in tuberculosis control and smoking. We estimated case
detection and treatment success rates by regressing curves
against data from expert panels and statistical extrapolations.
41
This procedure might overestimate the impact of ongoing
treatment efforts on tuberculosis control.
41 We also lacked
longitudinal data on annual smoking prevalence in each WHO
region and had to estimate smoking prevalence from tobacco
demanddata.Becausetobaccocompaniesareusinglesstobacco
per cigarette than in previous years and sales of informal
cigarettes are not always reported (such as bidis, which are
thought to deliver higher smoke content than normal
cigarettes),
44 the same tobacco demand could indicate a rise in
the actual number of smokers, causing our method to
underestimate the risk of tuberculosis.
Strengths and weaknesses in relation to other
studies
Because smoking has had such a profound impact on
tuberculosis mortality in this model, it has rendered some
traditionaltuberculosisoutcomevariablespotentiallyunreliable.
Population attributable risk is commonly used to calculate the
impact of a risk factor on disease rates, but does not account for
thesecondarycasesproducedbyeachprimaryinfectiousdisease
case. Tuberculosis prevalence is also used to assess the success
of tuberculosis control efforts by international bodies and
nationalhealthministries.
30Butwhenacofactorsuchassmoking
increases both the risk of primary infection and the risk of
mortality, it remains unclear how prevalence will change,
because the mortality increase could partly or completely
outweigh the increase in incidence (Little’s law).
45 The model
presented here shows that point prevalence could fall because
ofsmoking’sheavyimpactonmortality,evenwhiletuberculosis
incidence remains increased, producing a false sense of
reassurance if we use prevalence statistics as a gauge of
tuberculosis programme efficacy. A dynamic mathematical
model such as ours captures these complex time dependent
trendsintuberculosisbetterthanlinearextrapolationtechniques
typically used to estimate the impact of smoking.
Implications of study findings
The passage of the WHO Framework Convention on Tobacco
Control and its ratification by 174 countries (as of July 2011)
providesnewopportunitiestoreducesmoking.
46Lessthan10%
of the world’s population, however, is currently covered by
effectivetobaccocontrolprogrammesandalthoughallthetreaty
parties must regularly report on progress, the reporting system
is imperfect and not fully enforced.
47
According to the model described here, tobacco smoking
substantiallyincreasestuberculosiscasesanddeathsworldwide
andmightdelaytheachievementoftuberculosismortalitygoals.
Tuberculosiscontroleffortsstillrelyheavilyontreatmentbased
control, with tobacco cessation infrastructure being minimally
integrated into control programmes. In the past, multinational
tobacco companies have attempted to persuade health
organisationstofocusoninfectiousdiseasesratherthantobacco
control.
48Ourresultsshowthatthisisafalsedichotomy:tobacco
control is tuberculosis control.
Unanswered questions and future research
We had insufficient information to incorporate a dose response
associationbetweenthedurationofsmokingordegreeofsmoke
exposure (for example, years of smoking or cigarettes per day)
and tuberculosis risk, alternative tobacco products, or other
smoke effects (for example, use of hookahs or indoor air
pollution);sexspecificaspectsoftuberculosispathogenesis(for
example,potentialsexdifferencesinpathogenesis,whichcould
synergise with smoking’s increased prevalence in men); or the
potential implications of smoking on treatment adherence and
resistance to tuberculosis drugs. We followed traditional
tuberculosis models by simulating people older than 15 years,
since they account for the majority of transmission, and
parameters used to describe childhood tuberculosis remain
poorly understood.
25
Effects of passive smoking and interactions between HIV and
smoking also remain uncertain because of limited data from
which to base model parameters. Passive smoking in particular
could greatly amplify the number of tuberculosis cases
attributable to smoking. Few studies have reviewed the effect
of passive smoking on tuberculosis, and the subject merits
further investigation.
Finally,aseffortsareunderwaytoproposenewtargetsafterthe
2015deadlineforthemillenniumdevelopmentgoals,newgoals
and prospects for tuberculosis control should consider the need
to model host susceptibility factors such as tobacco when
accounting for the potential success or failure of, on one hand,
tobacco industry efforts to expand markets in developing
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tobacco control programmes. Smoking targets can also assist
with targets in tuberculosis control. Small scale studies of the
impact of smoking cessation on tuberculosis outcomes have
suggested substantial benefits from tobacco cessation, but data
are preliminary.
49
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RESEARCHWhat is already known on this topic
Smoking has been linked to increased individual risk of tuberculosis infection and mortality, but its impact on future
population rates of tuberculosis is unclear
We developed a mathematical model to estimate how future smoking trends can affect tuberculosis control
What this study adds
The model predicted that smoking could produce an excess of 18 million tuberculosis cases and 40 million deaths from
tuberculosis worldwide, between 2010 and 2050
Smoking is expected to delay achievement of the millennium development goal in tuberculosis mortality control
Aggressive tobacco control could avert 27 million deaths from tuberculosis attributable to smoking by 2050
Tables
Table 1| Values of model parameters
Reference
HIV positive
geometric mean
HIV negative
geometric mean
HIV positive mean of log
(SD)
HIV negative mean of
log (SD) Model parameter and definition (unit)
11 9.73 9.73 2.26 (0.12) 2.26 (0.12) c: close contact and transmission rate
(person/year)
12 0.29 0.60 −1.23 (0.15) −0.51 (0.05) f: active tuberculosis cases that are infectious
(proportion)
13 N/a N/a Varied* Varied* b: birth rate (per year)
12, 14 0.10 0.02 −2.32 (0.02) −3.89 (0.27) μ: background (non-tuberculosis) mortality rate
in non-smokers (per year)
15 0.10 0.03 −2.27 (0.02) −3.62 (0.39) μS: background (non-tuberculosis) mortality rate
in smokers (per year)
11, 12 0.91 0.30 −0.08 (0.06) −1.21 (0.14) μT: mortality rate due to tuberculosis (per year)
12 0.60 0.15 −0.54 (0.15) −1.92 (0.24) p: newly infected individuals with primary
progressive disease (proportion)
16 N/a N/a Varied† Varied† δ: active tuberculosis cases detected
(proportion)
17 2.89 0.62 0.46 (0.29) −0.20 (0.40) ε: detection and treatment rate (per year)
16 N/a N/a Varied‡ Varied‡ κ: detected cases that are successfully treated
(proportion)
12 0.08 0.20 −2.54 (0.46) −1.61 (0.11) σ: rate of natural self-cure (per year)
12 0.13 1.66×10
−4 −1.98 (0.26) −8.68 (0.27) ν: reactivation rate of latency to active
tuberculosis (per year)
12 0.74 0.33 −0.33 (0.14) −1.09 (0.30) χ: reinfected individuals who undergo primary
progression (proportion)
10 N/a N/a 2.0 (1.5 to 2.6) 2.0 (1.5 to 2.6) rST: tuberculosis infection in smokers (RR (95%
CI))§
10 N/a N/a 2.6 (1.8 to 3.6) 2.6 (1.8 to 3.6) rSD: tuberculosis mortality in smokers (RR (95%
CI))§
RR=relative risk. 95% CI=95% confidence intervals. Variables sampled from log-normal distributions. Geometric means given for reference. Web appendix provides
details on incorporation of HIV, case detection, and treatment success rates. *Varied by year; see reference.
†Varied by location and year; see text.
‡Varied by location and year; see web appendix.
§See table 3 in web appendix for primary data.
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RESEARCHTuberculosis mortality Tuberculosis prevalence
Region
Estimated year of achievement
Goal rate (per
100 000)
Estimated year of achievement
Goal rate (per
100 000) With smoking Without smoking With smoking Without smoking
Never* Never* 16 Never* Never* 137 Africa
2029‡ 2006‡ 4 1999† 2000 49 Americas
2062‡ 2014‡ 17 2020 2019 132 Eastern
Mediterranean
2048 2024 6 2027† 2030 48 Europe
2033‡ 2007‡ 24 2008† 2009 188 South East Asia
Never*‡ 2009‡ 17 2001† 2013 150 Western Pacific
Table 2 Effect of smoking on achievement of millennium development goal target to control tuberculosis prevalence and mortality
Years estimated with standard error of 3 years on each side. Mortality excludes HIV-tuberculosis cases (unlike fig 3), to accord with data in WHO report on
millennium development goal tuberculosis targets and current tuberculosis mortality estimates.
*Steady state rate is higher than target rate.
†Mortality from smoking can cause point prevalence to fall; hence prevalence target can be achieved earlier in the smoking model. This reduction reflects a rise
in deaths attributable to smoking rather than improved tuberculosis control.
‡WHO regions that will miss millennium development goal target to control tuberculosis mortality because of smoking.
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RESEARCHFigures
Fig 1 Mathematical model of tuberculosis infection, pathogenesis, and mortality. Model calculates the population prevalence
of smoking and of HIV in each year of the simulation, and then calculates how the number of new tuberculosis cases and
deaths are affected by the increased risk of infection or death posed by each risk factor. Model also incorporates rates of
reinfection, case detection, and treatment success, as well as non-tuberculosis mortality, and tuberculosis mortality (web
appendix)
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RESEARCHFig 2 Effect of smoking on tuberculosis incidence in WHO regions
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RESEARCHFig 3 Effect of smoking on tuberculosis mortality in WHO regions. Arrow=millennium development goal to reduce tuberculosis
mortality and prevalence by half by 2015
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5506 doi: 10.1136/bmj.d5506 Page 10 of 11
RESEARCHFig 4 Effect of smoking on tuberculosis prevalence statistics. Arrow=millennium development goal to reduce tuberculosis
mortality and prevalence by half by 2015
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